DR18 DataRelease
Release Date: 03/17/2016
| SDY56: Systems Biology of 2010 trivalent Influenza vaccine (TIV) in young and elderly (see companion study SDY61 2007, SDY270 2009, SDY119 2011) | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Study Objective To identify innate signatures that correlate with the magnitude, quality and persistence of B cell responses after vaccination with TIV in the young versus the elderly. Study Design Single center, open label study in which adult healthy volunteers with no contraindications to immunization will be vaccinated with TIV. Blood samples will be collected on Days D0 (at enrollment) and D1, D3, D7, D14, D30, D180 post vaccination to study innate and/or adaptive immunity markers. Even though influenza vaccination is considered safe, volunteers will be asked to report any local or systemic AEs from Day 0 (vaccination) to Day 7 in memory aids. Reactogenicity events will also be evaluated by injection site examination on visits at D0, D1, D3 and D7. Volunteers will be also asked to report local and systemic AEs developing the day of a blood draw. Additionally, only AEs considered related (unlikely, possibly, probably or definitely related) will be collected and reported in this study from Day 0 (vaccination) to Day 180. After Day 30 only related SAEs will be collected and reported. Study Duration 12 months (6 months accrual and 6 months follow-up period) |
||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3X9SKF8RQ | ||||||||||||
| Subjects: | 92 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY87: In-Depth Characterization of Immune Responses to Pneumovax Vaccination in Healthy Subjects | |||||||
| Status: | New | ||||||
| Description: | This study will measure the immune response to the Pneumovax vaccine The long-term goal is to develop improved vaccines to infectious diseases such as influenza. Blood will be collected from patients at several visits before and after vaccination. The blood will be used in a series of immunological tests to measure the strength and breadth of immune response. These assays may include T cell and B cell activation assays, microarray testing, Epimax, Epigen, and flow cytometry. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3AA0XR32D | ||||||
| Subjects: | 5 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY89: Systems Biology Analysis of the response to Licensed Hepatitis B Vaccine (Engerix-B) (see companion study SDY690) | |||||||||
| Status: | New | ||||||||
| Description: | This project will contribute to the overall vision and goals of this U19 by analyzing the role of adjuvants in the humoral response to hep B vaccination in healthy individuals. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3AYWX8NOT | ||||||||
| Subjects: | 50 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY112: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2011 (See companion studies SDY311 2010 / SDY312 2009 / SDY314 2008 / SDY315 2012) | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M320H8XYFG | ||||||||||||
| Subjects: | 93 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY113: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID/LAIV) in 2011 | |||||||||||||||||
| Status: | New | ||||||||||||||||
| Description: | To study the plasmablast response to influenza vaccines | ||||||||||||||||
| Program/Contract: |
|
||||||||||||||||
| DOI: | 10.21430/M3KPFS7KXI | ||||||||||||||||
| Subjects: | 70 | ||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||
| Publications: |
|
||||||||||||||||
| Resources: |
|
||||||||||||||||
| Assays: |
|
||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||
| SDY278: Optimization FACS panels | |||||||
| Status: | New | ||||||
| Description: | Optimization of ICS and phenotyping panels for the Mal067 study using cryopreserved PBMC samples from the SAC cohort | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M392SKIDA9 | ||||||
| Subjects: | 1 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY289: Live Kidney Donor Study (RELIVE-01) | |||||||
| Status: | New | ||||||
| Description: | The purpose of this study was to establish a multi-center kidney donor database containing renal failure, cardiovascular and overall mortality information for the complete cohorts of kidney donors who underwent living donor uninephrectomy. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3DM0S6FPM | ||||||
| Subjects: | 8922 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY290: Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study (RELIVE-04) | |||||||
| Status: | New | ||||||
| Description: | The goal of this study is to determine the long-term risks of donor nephrectomy, compared to appropriate control subjects. This study built on information generated from RELIVE-01, a separate but related retrospective study. Through direct contact with previous living kidney donors this study examined the contribution of living kidney donation to the future development of hypertension, proteinuria, renal insufficiency or renal failure and anemia, the potential through these factors or others for increased cardiovascular risk for clinical events including myocardial infarction (MI), congestive heart failure (CHF), need for coronary artery bypass grafting (CABG) or percutaneous coronary angioplasty (PTCA) revascularization, and the impact of living kidney donation on quality of life (QOL) and financial status, compared to applicable control subjects and populations. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M39RJDHJVB | ||||||
| Subjects: | 196 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY291: Live Kidney Donor Study -Renal Function Study (RELIVE-06) | |||||||
| Status: | New | ||||||
| Description: | As part of a cross-sectional study of living kidney donors from 5 to more than 50 years following donor nephrectomy, this study's goal is to accurately measure current Glomerular Filtration Rate (GFR), then to look at the change in GFR from pre to post donation and from early to late time points after donation. This study builds on information generated from RELIVE-01 and RELIVE-04. Through direct contact with previous living kidney donors, this study aims to quantify changes in renal function (measured GFR) from pre to early post donation using data already collected in a related retrospective study (RELIVE 01), and the change in renal function from early (in the first 2 years) post donation to late (beyond the first 2 years) post donation by repeating a GFR measurement. Cross-sectional GFR measurements from black donors compared to white donors matched for age, sex, weight and time from donation will provide data on differences in GFR late after donor nephrectomy by race. When compared to GFR estimates using predictive equations at each of these time points, we can evaluate the accuracy of estimated GFR in white and black donor populations. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M33MG60QVQ | ||||||
| Subjects: | 413 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY292: RELIVE Informed Consent Study (RELIVE-03) | |||||||
| Status: | New | ||||||
| Description: | The goal of this study was to study informed consent by the living donor. This study used surveys to evaluate the understanding of risk and psychological pressure that living organ donors felt when making the decision to donate. It compared participants' answers across geographic, racial and socio-economic backgrounds. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3G310ZBSI | ||||||
| Subjects: | 636 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY294: Live Lung Donor Cross-sectional Cohort Study (RELIVE-05) | |||||||
| Status: | New | ||||||
| Description: | The Live Lung Donor Cross-sectional Cohort Study (RELIVE-05) aimed to determine the effects of live lung donation on lung function, quality of life, morbidity, psychosocial status, satisfaction with live lung donation, and decision-making associated with live lung donation. This study built on the separate but related RELIVE-02 retrospective study that assessed the effects of live lung donation on survival and short-term morbidity. This multicenter cross-sectional cohort study invited the RELIVE-02 living former live lung donors to undergo questionnaire and pulmonary function test assessments to further determine the long-term outcomes of live lung donation. This study used preoperative donor pulmonary function data and normative data to assist with assessing the effects of live lung donation on lung donors. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M38LFF1QAA | ||||||
| Subjects: | 162 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| SDY299: Systems Biology Analysis of the response to Licensed Hepatitis B Vaccine (HEPLISAV) in Whole Blood (see companion studies SDY816 and SDY690) | |||||||
| Status: | New | ||||||
| Description: | This project will contribute to the overall vision and goals of this U19 by analyzing the role of adjuvants in the humoral response to hep B vaccination in healthy individuals. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M34QI37OT9 | ||||||
| Subjects: | 25 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY300: Healthy Human DC and monocyte subsets transcriptional regulations in response to Fluzone 2010-2011 and pneumococcal vaccinations | |||||||
| Status: | New | ||||||
| Description: | The described experiments in this study were designed to deconvolute the molecular signature observed in the whole blood of healthy subsets at early time points following the administration of Fluzone 2010-2011 vaccines. RNA-seq data generated from sorted purified cell populations, including mDC and monocyte subsets will permit us to reveal distinct roles that DC and monocyte subsets play in eliciting immune responses to vaccines against flu in healthy adults using system biology approaches. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3FJJ9G9ZZ | ||||||
| Subjects: | 10 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY305: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID) in 2012 | |||||||||||||||||
| Status: | New | ||||||||||||||||
| Description: | To study the plasmablast response to 2012 seasonal inactivated influenza vaccine | ||||||||||||||||
| Program/Contract: |
|
||||||||||||||||
| DOI: | 10.21430/M3U2R9IV87 | ||||||||||||||||
| Subjects: | 25 | ||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||
| Publications: | None | ||||||||||||||||
| Resources: |
|
||||||||||||||||
| Assays: |
|
||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||
| SDY311: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2010 (See companion studies SDY315 2012 / SDY312 2009 / SDY314 2008 / SDY112 2011) | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M33MSDRJ55 | ||||||||||||
| Subjects: | 76 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY312: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2009 (See companion studies SDY315 2012 / SDY314 2008 / SDY311 2010 / SDY112 2011) | |||||||||||
| Status: | New | ||||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3G230OYOM | ||||||||||
| Subjects: | 84 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: | None | ||||||||||
| SDY314: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2008 (See companion studies SDY315 2012 / SDY312 2009 / SDY311 2010 / SDY112 2011) | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3WZ7XK2GG | ||||||||||||
| Subjects: | 92 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY315: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination (TIV) - 2012 (See companion studies SDY311 2010 / SDY312 2009 / SDY314 2008 / SDY112 2011) | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3CJT3NCT2 | ||||||||||||
| Subjects: | 74 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| SDY364: Systems Biology Approach to Study Influenza Vaccine 2012-13 in Healthy Children (see companion studies SDY144, SDY368, SDY387) | |||||||||||
| Status: | New | ||||||||||
| Description: | The treatment of pediatric immune system dysfunctions depends upon the basic understanding of its molecular and cellular components, as well as the inherent relationships between these components. Specifically, such knowledge requires an appreciation of B-Iymphocytes, T lymphocytes, natural killer cells and dendritic cells. Research investigating these cells and their functions necessitates the availability and acquisition of peripheral blood samples from healthy children to form control data groups against which various experimental conditions can be measured. Volunteers will be asked to donate blood samples to be used to further study the circulating dendritic cell subpopulations and establish their normal ranges. Blood samples will also be used to isolate antigen specific T lymphocytes, serve as a monocyte source and establish gene signatures. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3U11KLQFF | ||||||||||
| Subjects: | 23 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY368: Systems Biology Approach to Study Influenza Vaccine 2013-14 in Healthy Children (see companion studies SDY364, SDY144, SDY387) | |||||||||||
| Status: | New | ||||||||||
| Description: | The treatment of pediatric immune system dysfunctions depends upon the basic understanding of its molecular and cellular components, as well as the inherent relationships between these components. Specifically, such knowledge requires an appreciation of B-Iymphocytes, T lymphocytes, natural killer cells and dendritic cells. Research investigating these cells and their functions necessitates the availability and acquisition of peripheral blood samples from healthy children to form control data groups against which various experimental conditions can be measured. Volunteers will be asked to donate blood samples to be used to further study the circulating dendritic cell subpopulations and establish their normal ranges. Blood samples will also be used to isolate antigen specific T lymphocytes, serve as a monocyte source and establish gene signatures. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3VUYLMJSR | ||||||||||
| Subjects: | 22 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY369: Systems Biology Approach to Study Influenza Vaccine in Children with Autoimmunity (Juvenile Dermatomyositis JDM) 2011/2012 Cohort (see companion studies SDY376, SDY372, SDY645) | |||||||||||
| Status: | New | ||||||||||
| Description: | This Project will study vaccine responses in healthy and sick children. It will address the following questions: 1) which are the best biomarkers of protective immune response to influenza vaccine in healthy children; 2) how unique autoimmune backgrounds set the stage for responsiveness/unresponsiveness to vaccines; 3) whether vaccination contributes to increase the breadth of autoimmunity in a disease-specific manner. Ultimately, we expect that these studies will shed light on basic aspects of humoral immune responses to vaccines and will permit us to discover biomarkers of response that can be applied to healthy children and to the general population. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M38SIW861C | ||||||||||
| Subjects: | 4 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY372: Systems Biology Approach to Study Influenza Vaccine in Children with Autoimmunity (Juvenile Dermatomyositis JDM) 2012/2013 Cohort (see companion studies (SDY369, SDY376, SDY645) | |||||||||||
| Status: | New | ||||||||||
| Description: | This Project will study vaccine responses in healthy and sick children. It will address the following questions: 1) which are the best biomarkers of protective immune response to influenza vaccine in healthy children; 2) how unique autoimmune backgrounds set the stage for responsiveness/unresponsiveness to vaccines; 3) whether vaccination contributes to increase the breadth of autoimmunity in a disease-specific manner. Ultimately, we expect that these studies will shed light on basic aspects of humoral immune responses to vaccines and will permit us to discover biomarkers of response that can be applied to healthy children and to the general population. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3NOD39G06 | ||||||||||
| Subjects: | 19 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY376: Systems Biology Approach to Study Influenza Vaccine in Children with Autoimmunity (Juvenile Dermatomyositis JDM) 2013/2014 Cohort (see companion studies SDY369, SDY372, SDY645) | |||||||||||
| Status: | New | ||||||||||
| Description: | This Project will study vaccine responses in healthy and sick children. It will address the following questions: 1) which are the best biomarkers of protective immune response to influenza vaccine in healthy children; 2) how unique autoimmune backgrounds set the stage for responsiveness/unresponsiveness to vaccines; 3) whether vaccination contributes to increase the breadth of autoimmunity in a disease-specific manner. Ultimately, we expect that these studies will shed light on basic aspects of humoral immune responses to vaccines and will permit us to discover biomarkers of response that can be applied to healthy children and to the general population. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M37IMDD0RO | ||||||||||
| Subjects: | 13 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| SDY395: Immune Responses to Influenza-Like Illness | |||||||
| Status: | New | ||||||
| Description: | To investigate the nasal transcriptional response and peripheral plasmablast response in acute influenza infection | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M33RY4IXN7 | ||||||
| Subjects: | 33 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY406: Immune Responses to Influenza-Like Illness | |||||||||
| Status: | New | ||||||||
| Description: | To investigate the nasal transcriptional response and peripheral plasmablast response in acute influenza infection | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3U4SDFNWN | ||||||||
| Subjects: | 6 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: | None | ||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY416: Study to measure the immune response to the influenza vaccine in patients with chronic plaque psoriasis | |||||||
| Status: | New | ||||||
| Description: | Interleukin-12 (IL-12) and interleukin-23 are heterodimeric cytokines, with a common p40 subunit and a unique chain (IL-12p35 and IL-23p19). The p40 subunit of both interleukins binds to the transmembrane IL-12 receptor-beta1 (IL-12R ) on the surface of T lymphocytes and natural killer cells. Ustekinumab is a fully human monoclonal antibody, anti-IL12p40, which binds to the p40 subunit of IL-12 and IL-23 with high affinity and specificity, inhibiting the activity of both interleukins. Ustekinumab has proven to be highly effective in the treatment of chronic plaque psoriasis, with up to 76% of patients achieving a 75% reduction in their psoriasis area and severity index (PASI-75).1, It is routinely recommended that psoriasis patients treated with biologic therapies such as ustekinumab be vaccinated annually with the influenza vaccine. We can thus assess the importance of these cytokines in the immune response to vaccination by comparing the immune response to influenza vaccination of psoriasis patients treated with ustekinumab with that of patients who are not receiving this treatment. We will assess gene expression profiles and white blood cell subsets in the blood of psoriasis patients before vaccination and at multiple time-points after vaccination. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3KG2XM196 | ||||||
| Subjects: | 45 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY421: Clonal B cell response to naturally occurring pathogens causing tissue specific immune responses in human | |||||||
| Status: | New | ||||||
| Description: | Elucidate the trafficking specificity, or diversity, of clonal B cell responses to mucosae-associated illnesses or infections in vivo. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3S1P8RAII | ||||||
| Subjects: | 4 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY422: DFCI HLA typing | |||||||
| Status: | New | ||||||
| Description: | We used an in situ synthesized DNA-based microarray method that contains thousands of probes representing a complete overlapping set covering 1,610 clinically relevant HLA class I alleles accompanied by computational tools for assigning HLA type to 4-digit resolution. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M354GUQI65 | ||||||
| Subjects: | 72 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY460: B and T Cell Determinants of Influenza Vaccine Responses in the Elderly 2008 (see companion study SDY773) | |||||||
| Status: | New | ||||||
| Description: | Application of high-throughput DNA sequencing of the IGH gene rearrangements to study the B cell repertoires over two successive years in 27 individuals ranging in age from 20 to 89 years old. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M34OUDCFO2 | ||||||
| Subjects: | 27 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY461: Monitoring of tissue-specific immune responses in man to naturally occurring pathogens using mass cytometric monitoring | |||||||
| Status: | New | ||||||
| Description: | Elucidate the trafficking specificity, or diversity, of clonal B cell responses to mucosae-associated illnesses or infections in vivo. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M31UBL340J | ||||||
| Subjects: | 7 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY465: Exploring the human maternal microbiome and its contribution to preterm birth | |||||||
| Status: | New | ||||||
| Description: | Preterm births occur in 12 percent of pregnancies. Preterm infants are at risk for long term health problems such as impaired hearing and vision, cerebral palsy and developmental delays. This study will characterize the human maternal microbiome and host response profiles associated with term and preterm births and identify features of each that are predicitive of preterm labor and delivery | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3D491LGDT | ||||||
| Subjects: | 47 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| SDY472: Plasmablast response to inactivated and live attenuated influenza vaccines (TIV3/TIV3 ID) in 2013 | |||||||||
| Status: | New | ||||||||
| Description: | This study will be conducted with up to 40 generally healthy children | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3KHTSSSN7 | ||||||||
| Subjects: | 24 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: | None | ||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY478: T cell responses to H1N1v and a longitudinal study of seasonal influenza vaccination - 2013 | |||||||||
| Status: | New | ||||||||
| Description: | Systems biology approach to examine effects of seasonal flu vaccination in adults of different ages on gene expression, cytokine stimulation and serum cytokines with parameters such as immune senescence to uncover new markers and mechanisms behind failure of immune function in many older people. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M3YEJTSS29 | ||||||||
| Subjects: | 70 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: | None | ||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: | None | ||||||||
| SDY506: CD107 CTL assay | |||||||
| Status: | New | ||||||
| Description: | CD107A/B assay against influenza infected lung epithelium. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3XV14B6A4 | ||||||
| Subjects: | 1 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY508: Humoral responses to West Nile virus | |||||||
| Status: | New | ||||||
| Description: | Integrate two high-throughput technologies namely, microengraving-based screening of primary B cells and next-generation sequencing to examine the relationship between the diversity and quality of humoral responses raised and the severity of disease. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3WVUCYBW9 | ||||||
| Subjects: | 12 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY517: Natural Killer cells in resistance to infection with West Nile virus | |||||||
| Status: | New | ||||||
| Description: | Examine the response of primary NK cells from subjects with a history of asymptomatic or severe infection with West nile virus | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3NI5JARF2 | ||||||
| Subjects: | 14 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY520: Immunologic and genomic signatures of influenza vaccine response - 2013 (see companion studies SDY63, SDY404, SDY400) | |||||||
| Status: | New | ||||||
| Description: | Project 1: Immunologic and genomic signatures of influenza vaccine response - year4 2013 | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3KVVHM735 | ||||||
| Subjects: | 61 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY523: Peptide display hierarchy protocol | |||||||
| Status: | New | ||||||
| Description: | Peptide display hierarchy | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3UJNPPHFY | ||||||
| Subjects: | 1 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY597: DC transcriptomics in response to vaccines | |||||||
| Status: | New | ||||||
| Description: | The mechanisms by which microbial vaccines interact with human APCs remain elusive. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3AC1WMBDO | ||||||
| Subjects: | 20 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY640: Immunologic and genomic signatures of influenza vaccine response - 2014 | |||||||
| Status: | New | ||||||
| Description: | Project 1: Immunologic and genomic signatures of influenza vaccine response - year5 2014 | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3A6GYD5L0 | ||||||
| Subjects: | 37 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY645: Systems Biology Approach to Study Influenza Vaccine in Children with Autoimmunity (Juvenile Dermatomyositis JDM) 2014/2015 Cohort (see companion studies SDY369, SDY376, SDY372) | |||||||||||
| Status: | New | ||||||||||
| Description: | This Project will study vaccine responses in healthy and sick children. It will address the following questions: 1) which are the best biomarkers of protective immune response to influenza vaccine in healthy children; 2) how unique autoimmune backgrounds set the stage for responsiveness/unresponsiveness to vaccines; 3) whether vaccination contributes to increase the breadth of autoimmunity in a disease-specific manner. Ultimately, we expect that these studies will shed light on basic aspects of humoral immune responses to vaccines and will permit us to discover biomarkers of response that can be applied to healthy children and to the general population. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M35HMSDTHH | ||||||||||
| Subjects: | 11 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: | None | ||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: | None | ||||||||||
| SDY667: The immune signature of palmoplantar pustulosis | |||||||
| Status: | New | ||||||
| Description: | This study will compare adult patients with CPP(chronic plaque type psoriasis ), who are currently not undergoing topical, systemic or biologic treatment and matched healthy controls. Baseline demographics and psoriasis history will be recorded. All PPP patients will be comprehensively phenotyped and psoriasis severity assessed including the body surface area (BSA) involved, Psoriasis Area and Severity Index (PASI), Physicians Global assessment (PGA) and Dermatology Life Quality Index (DLQI). | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M34NBAVDGJ | ||||||
| Subjects: | 50 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY675: Heritable influence on the B and T cell receptor repertoire | |||||||
| Status: | New | ||||||
| Description: | The adaptive immune systems capability to protect the body requires a highly diverse lymphocyte antigen receptor repertoire. However, the influence of individual genetic and epigenetic differences on these repertoires is frequently underestimated. By leveraging the unique characteristics of B, CD4+ T, and CD8+ T lymphocyte subsets isolated from monozygotic twins, we have elucidated the impact of heritable factors on the V(D)J recombination process and have shown that the repertoires of both naive and antigen experienced cells are subject to biases resulting from initial recombination differences. Moreover, we show that the relative usage of V and J gene segments is chromosomally biased, with approximately 1.5 times as many rearrangements originating from a single chromosome. These data refine our understanding of the heritable mechanisms affecting the repertoire, and show that bias exists on a chromosome-wide level. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3XMYVQI9X | ||||||
| Subjects: | 10 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY690: Systems Biology Study to Investigate Immune Correlates to Hepatitis B Vaccine Engerix-B comparing cellular responses and gene expression patterns between PBMCs (cell sorts) and whole blood samples (see companion studies SDY816 and SDY299) | |||||||
| Status: | New | ||||||
| Description: | This project will contribute to the overall vision and goals of this U19 by analyzing the role of adjuvants in the humoral response to hep B vaccination in healthy individuals. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3F8W7VA7O | ||||||
| Subjects: | 12 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY702: Human T Cell Profile | |||||||
| Status: | New | ||||||
| Description: | We present a quantitative, system-wide analysis of T cell differentiation, homeostasis and persistence in blood, lymphoid, and mucosal tissues obtained from a highly diverse cohort of 56 organ donors aged 3?73 years. We incorporate an analysis of naive, memory, and effector T cells with functional markers of homeostasis, activation, and tissue residence along with quantification of in situ turnover and TCR clonal distribution to reveal distinct patterns of compartmentalization, maintenance and proliferation of human T cells. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M39EBHNRYF | ||||||
| Subjects: | 56 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY753: Investigating Alterations to the Nasal Microbiome after Vaccination with LAIV | |||||||
| Status: | New | ||||||
| Description: | The goal of this proposal is to characterize alterations to the nasal microbiome after vaccination with the 2012-2013 seasonal LAIV and to correlate these changes with LAIV-specific immune responses (A/California/7/2009 (H1N1) and A/Victoria/361/2011 (H3N2)). | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3ENN2D3SZ | ||||||
| Subjects: | 47 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY756: Histology post influenza | |||||||
| Status: | New | ||||||
| Description: | Histological analysis in lung post infection of B6 or B6 A02 transgenic AAD mice with influenza A/PR8/34 virus | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3EWWO0ERE | ||||||
| Subjects: | 1 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| SDY773: B and T Cell Determinants of Influenza Vaccine Responses in the Elderly 2009 (see companion study SDY460) | |||||||
| Status: | New | ||||||
| Description: | Application of high-throughput DNA sequencing of the IGH gene rearrangements to study the B cell repertoires over two successive years in 27 individuals ranging in age from 20 to 89 years old. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M35OPGLUTH | ||||||
| Subjects: | 27 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||